These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9867151

  • 1. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 2. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
    Salako QA, O'Donnell RT, DeNardo SJ.
    J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
    [Abstract] [Full Text] [Related]

  • 3. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR, Raubitschek A, Shively JE.
    Bioconjug Chem; 1994 Apr; 5(6):565-76. PubMed ID: 7873659
    [Abstract] [Full Text] [Related]

  • 4. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 5. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [Abstract] [Full Text] [Related]

  • 6. Antibody responses to macrocycles in lymphoma.
    DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ.
    J Nucl Med; 1996 Mar 01; 37(3):451-6. PubMed ID: 8772643
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct 01; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF.
    J Nucl Med; 1995 May 01; 36(5):829-36. PubMed ID: 7738660
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
    Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, Meares CF.
    Cancer; 1994 Feb 01; 73(3 Suppl):779-86. PubMed ID: 8306260
    [Abstract] [Full Text] [Related]

  • 10. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 01; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA.
    Cancer Res; 1992 Feb 15; 52(4):904-11. PubMed ID: 1737353
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL.
    Anticancer Res; 2000 Feb 15; 20(5C):3647-55. PubMed ID: 11268433
    [Abstract] [Full Text] [Related]

  • 15. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M, Ferrari M, Chinol M, Stabin MG, Grana C, Prisco G, Robertson C, Tosi G, Paganelli G.
    Eur J Nucl Med; 1999 Feb 15; 26(2):110-20. PubMed ID: 9933344
    [Abstract] [Full Text] [Related]

  • 16. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ.
    Clin Cancer Res; 1999 Mar 15; 5(3):533-41. PubMed ID: 10100704
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 Mar 15; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 19. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
    Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, Meares CF.
    J Nucl Med; 1990 Apr 15; 31(4):473-9. PubMed ID: 2324823
    [Abstract] [Full Text] [Related]

  • 20. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, Mishra AK.
    Cancer Biol Ther; 2005 Aug 15; 4(8):854-60. PubMed ID: 16082184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.